title: Small dense LDL is more susceptible to glycation than more buoyant LDL in Type 2 diabetes.
abstract: Glycation of apoB (apolipoprotein B) of LDL (low-density lipoprotein) increases its atherogenicity. Concentrations of both serum glyc-apoB (glycated apoB) and SD-LDL (small dense LDL) (syn LDL3; D=1.044-1.063 g/ml) are increased in diabetes and are closely correlated. We studied whether SD-LDL is more susceptible to glycation in vitro than more buoyant LDL in statin- and non-statin-treated Type 2 diabetes mellitus. Serum SD-LDL apoB and glyc-apoB on statins was 20±2 (means±S.D.) and 3.6±0.41 compared with 47±3 and 5.89±0.68 mg/dl in those not receiving statins (P<0.001 and <0.01, respectively). There was a dose-dependent increase in glycation on incubation of LDL subfractions with glucose, which was accompanied by an increase in LPO (lipid peroxide) and electrophoretic mobility and a decrease in free amino groups. SD-LDL was more susceptible to these changes than more buoyant LDL. Both SD-LDL and more buoyant LDL from statin-treated patients were less susceptible to glycation. There were fewer free amino groups on LDL subfractions from statin-treated patients, which may contribute to this resistance. In conclusion, greater susceptibility of SD-LDL to glycation is likely to contribute to the raised levels of circulating glyc-apoB in diabetes. Statins are associated with lower levels of both SD-LDL and glyc-apoB.
authors.affiliation: Cardiovascular Research Group, School of Biomedicine, University of Manchester, Manchester, UK.
authors.forename: Nahla N
authors.initials: NN
authors.lastname: Younis
authors.forename: Handrean
authors.initials: H
authors.lastname: Soran
authors.forename: Philip
authors.initials: P
authors.lastname: Pemberton
authors.forename: Valentine
authors.initials: V
authors.lastname: Charlton-Menys
authors.forename: Mohamed M
authors.initials: MM
authors.lastname: Elseweidy
authors.forename: Paul N
authors.initials: PN
authors.lastname: Durrington
mesh_terms: D001055:Apolipoproteins B / Q000737:chemistry / Q000378:metabolism*; D050197:Atherosclerosis / Q000378:metabolism; D001786:Blood Glucose / Q000378:metabolism; D003327:Coronary Disease / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism*; D024202:Electrophoretic Mobility Shift Assay; D005260:Female; D006031:Glycosylation; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000188:drug therapy / Q000378:metabolism*; D008077:Lipoproteins, LDL / Q000737:chemistry / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010316:Particle Size
chemical_list: D001055:Apolipoproteins B; D001786:Blood Glucose; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008077:Lipoproteins, LDL